Construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity

ObjectiveTo establish a new patient-derived xenograft (PDX) model of human liver cancer by inoculating the complex of human primary liver cancer cells and a novel microcarrier (microcarrier 6) into mice with normal immune function. MethodsPrimary liver cancer cells were isolated and extracted from t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	TANG Huixin
Formato:	article
Lenguaje:	ZH
Publicado:	Editorial Department of Journal of Clinical Hepatology 2021
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/309ed71879e7419ba0f168fd34394941
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:309ed71879e7419ba0f168fd34394941
record_format	dspace
spelling	oai:doaj.org-article:309ed71879e7419ba0f168fd343949412021-11-17T10:56:52ZConstruction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity1001-5256https://doaj.org/article/309ed71879e7419ba0f168fd343949412021-11-01T00:00:00Zhttp://www.lcgdbzz.org/cn/article/doi/10.3969/j.issn.1001-5256.2021.11.019https://doaj.org/toc/1001-5256ObjectiveTo establish a new patient-derived xenograft (PDX) model of human liver cancer by inoculating the complex of human primary liver cancer cells and a novel microcarrier (microcarrier 6) into mice with normal immune function. MethodsPrimary liver cancer cells were isolated and extracted from the fresh human liver cancer tissue of five patients and were then co-cultured with microcarrier 6 to construct a three-dimensional tumor cell culture model in vitro. According to the type of graft, 75 male C57BL/6 mice were divided into cell control group, microcarrier control group, and experimental group (each sample corresponded to three groups, with 15 groups in total and 5 mice in each group). The liver cancer cell-microcarrier complex was implanted into the mice by subcutaneous inoculation, and tumor formation time, tumor formation rate, and histopathological manifestations were observed. The Fisher’s exact test was used for comparison of categorical data between two groups. ResultsAs for the liver cancer cells from the five patients, tumor formation was observed in the mice corresponding to three patients. In these three experiments, tumor formation was not observed in the control groups and was only observed in the experimental groups, and 12 of the 15 mice in the experimental groups had successful tumor formation, with a tumor formation rate as high as 80%, which was significantly different from that in the cell control groups and the microcarrier control groups (all P＜0.05). The tumor formation time was 5-7 days; the xenograft tumor grew rapidly, and HE staining showed nested or flaky cells with obvious heteromorphism, with the presence of pathological mitosis; immunohistochemical staining showed positive CK8/18, Hep, and Gpc-3, which was in accordance with the characteristics of human liver cancer cells. ConclusionThis experiment successfully establishes a new PDX model of human liver cancer based on the complex of microcarrier 6 and human primary liver cancer cells in mice with normal immunity. This model can be used to better elucidate the mechanism of the development and progression of liver cancer in the body with normal immunity, and besides, it also provides a new animal model with higher value for the precise treatment of liver cancer.TANG HuixinEditorial Department of Journal of Clinical HepatologyarticleDiseases of the digestive system. GastroenterologyRC799-869ZHLinchuang Gandanbing Zazhi, Vol 37, Iss 11, Pp 2584-2588 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Diseases of the digestive system. Gastroenterology RC799-869 TANG Huixin Construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity
description	ObjectiveTo establish a new patient-derived xenograft (PDX) model of human liver cancer by inoculating the complex of human primary liver cancer cells and a novel microcarrier (microcarrier 6) into mice with normal immune function. MethodsPrimary liver cancer cells were isolated and extracted from the fresh human liver cancer tissue of five patients and were then co-cultured with microcarrier 6 to construct a three-dimensional tumor cell culture model in vitro. According to the type of graft, 75 male C57BL/6 mice were divided into cell control group, microcarrier control group, and experimental group (each sample corresponded to three groups, with 15 groups in total and 5 mice in each group). The liver cancer cell-microcarrier complex was implanted into the mice by subcutaneous inoculation, and tumor formation time, tumor formation rate, and histopathological manifestations were observed. The Fisher’s exact test was used for comparison of categorical data between two groups. ResultsAs for the liver cancer cells from the five patients, tumor formation was observed in the mice corresponding to three patients. In these three experiments, tumor formation was not observed in the control groups and was only observed in the experimental groups, and 12 of the 15 mice in the experimental groups had successful tumor formation, with a tumor formation rate as high as 80%, which was significantly different from that in the cell control groups and the microcarrier control groups (all P＜0.05). The tumor formation time was 5-7 days; the xenograft tumor grew rapidly, and HE staining showed nested or flaky cells with obvious heteromorphism, with the presence of pathological mitosis; immunohistochemical staining showed positive CK8/18, Hep, and Gpc-3, which was in accordance with the characteristics of human liver cancer cells. ConclusionThis experiment successfully establishes a new PDX model of human liver cancer based on the complex of microcarrier 6 and human primary liver cancer cells in mice with normal immunity. This model can be used to better elucidate the mechanism of the development and progression of liver cancer in the body with normal immunity, and besides, it also provides a new animal model with higher value for the precise treatment of liver cancer.
format	article
author	TANG Huixin
author_facet	TANG Huixin
author_sort	TANG Huixin
title	Construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity
title_short	Construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity
title_full	Construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity
title_fullStr	Construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity
title_full_unstemmed	Construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity
title_sort	construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity
publisher	Editorial Department of Journal of Clinical Hepatology
publishDate	2021
url	https://doaj.org/article/309ed71879e7419ba0f168fd34394941
work_keys_str_mv	AT tanghuixin constructionofanewpatientderivedxenograftmodelofhumanlivercancerinmicewithnormalimmunity
_version_	1718425601168113664

Construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity

Ejemplares similares